FOLH1 and neoplasm: If the critical cell population, from which future tumour progression is derived, is characterized by continuing PSMA expression during ongoing ADT, PSMA-based radioligand therapy, which has already shown remarkable antitumour activity in the last-line setting [22–26], might also be a powerful therapeutic partner for ADT.